



## Mara Goldstein

Senior Analyst  
US Health Care – Biotechnology

[Mara.Goldstein@mizuhogroup.com](mailto:Mara.Goldstein@mizuhogroup.com)

+1 212 209 9445

- Mara joined Mizuho in November 2018 as a senior analyst based in New York, covering the biotechnology sector.
- Prior to Mizuho, Mara was senior biotechnology analyst and head of healthcare at Cantor Fitzgerald, before assuming the dual roles of research analyst and director of research at the firm.
- At Cantor, healthcare coverage grew to over 130 stocks spanning multiple sub-sectors. She helped launch Cantor's healthcare conference program.
- Prior to Cantor, Mara headed the healthcare team at Reuters Insight (Anian) and was later head of the research group. She also spent eight years at CIBC World Markets (now Oppenheimer) as executive director and senior analyst covering large-cap pharmaceuticals, drug delivery companies, and contract research organizations.
- Prior to CIBC, Mara was an associate analyst with Alex. Brown & Sons (now Deutsche Bank).
- Mara graduated from Purdue University with a BS in economics and minors in history and French.

## Coverage Universe

Adaptimmune Therapeutics, Inc.	ADAP
Arcus Biosciences, Inc.	RCUS
Autolus Therapeutics, plc	AUTL
Corvus Pharmaceuticals, Inc.	CRVS
CytomX Therapeutics, Inc.	CTMX
eFFECTOR Therapeutics, Inc.	EFTR
Erasca, Inc.	ERAS
Fate Therapeutics, Inc.	FATE
Immuneering Corporation	IMRX
IN8bio, Inc.	INAB
Incyte Corporation	INCY
Iovance Biotherapeutics, Inc.	IOVA
Leap Therapeutics, Inc.	LPTX
Merck & Co., Inc.	MRK
Nektar Therapeutics	NKTR
Neoleukin Therapeutics, Inc.	NLTX
TCR2 Therapeutics Inc.	TCRR
Verastem, Inc.	VSTM
Xencor, Inc.	XNCR